Bidiphar cooperates with Crearene AG to develop pioneering treatment solutions for dialysis patients

Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company and Crearene AG have just signed a memorandum of understanding to develop creatine treatment solutions for dialysis patients.

Dr. Uwe Riek, Chief Scientific Officer of Crearene and Dr. Frank Heideloff, CEO of Crearene during their visit to Bidiphar

Dr. Uwe Riek, Chief Scientific Officer of Crearene and Dr. Frank Heideloff, CEO of Crearene during a visit to Bidiphar. Photo: Bidiphar.

Information from Binh Dinh Pharmaceutical and Medical Equipment Joint Stock Company (Bidiphar), the Company announced the signing of a memorandum of understanding (MOU) with Crearene AG (headquartered in Frauenfeld, Switzerland) to develop creatine treatment solutions for dialysis patients. The goal of this cooperation is to sign a copyright transfer contract, bringing new advances in health care for dialysis patients.

According to Ms. Pham Thi Thanh Huong, General Director of Bidiphar, through this promising cooperation with Crearene AG, Bidiphar hopes to bring breakthrough improvements in dialysis treatment.

“Scientific research has shown that dialysis patients often have creatine deficiency, leading to fatigue and muscle weakness. By adding creatine to the treatment, we hope to significantly improve the quality of life of patients,” Ms. Huong mentioned.

Crearene AG is a Swiss-based medical technology company that brings together a team of researchers and scientists to develop innovative technologies to improve the quality of life for dialysis patients. Crearene's solutions promise significant improvements, helping thousands of dialysis patients significantly improve their health and daily life.

Bidiphar quoted Dr. Frank Heideloff, CEO of Crearene AG, as saying that currently, there are more than 3 million dialysis patients worldwide who need regular treatment.

“We are delighted to partner with Bidiphar to bring innovation to the market, improving the physical condition and overall health of the growing number of dialysis patients. Crearene’s patented technology, the result of many years of research into the use of creatine, combined with Bidiphar’s superior manufacturing capabilities, patient access and market knowledge in Vietnam, provide an excellent foundation for this effort,” said Crearene AG CEO.

Bidiphar added that over the past year, Bidiphar and Crearene have worked together to collect information and conduct necessary research. After this memorandum of understanding (MOU), Bidiphar's research center will continue to work closely with Crearene towards signing a copyright transfer contract to Vietnam. Thereby, Bidiphar will be the first unit in Vietnam and the region to have this technology.

Bidiphar is currently one of the market leaders in the product line of hemodialysis-peritoneal solutions to help treat patients undergoing dialysis in Vietnam.

Recently, Bidiphar was honored by Forbes Vietnam Magazine in the list of "Top 50 best listed enterprises" in 2024. This is the first time Bidiphar has achieved this position.

Source: https://baodautu.vn/bidiphar-hop-tac-crearene-ag-phat-trien-giai-phap-tien-phong-dieu-tri-cho-benh-nhan-chay-than-d220360.html